Business Description
Exagen Inc
NAICS : 541380
SIC : 8071
1261 Liberty Way, Suite C, Vista, CA, USA, 92081
Description
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.21 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.54 | |||||
| Debt-to-EBITDA | -1.02 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.68 | |||||
| Beneish M-Score | -2.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -18.4 | |||||
| 3-Year EBITDA Growth Rate | -24.6 | |||||
| 3-Year EPS without NRI Growth Rate | -4.8 | |||||
| 3-Year FCF Growth Rate | 4.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 10.74 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.59 | |||||
| 9-Day RSI | 20.61 | |||||
| 14-Day RSI | 28.98 | |||||
| 6-1 Month Momentum % | -10.18 | |||||
| 12-1 Month Momentum % | -41.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.3 | |||||
| Quick Ratio | 9.3 | |||||
| Cash Ratio | 7.98 | |||||
| Days Sales Outstanding | 79.34 | |||||
| Days Payable | 45.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -40.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.61 | |||||
| Operating Margin % | -79.34 | |||||
| Net Margin % | -85.36 | |||||
| ROE % | -45.84 | |||||
| ROA % | -30.78 | |||||
| ROIC % | -202.52 | |||||
| ROC (Joel Greenblatt) % | -306.93 | |||||
| ROCE % | -30.96 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.8 | |||||
| PB Ratio | 1.18 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| EV-to-EBIT | -0.94 | |||||
| EV-to-Forward-EBIT | -0.8 | |||||
| EV-to-EBITDA | -0.99 | |||||
| EV-to-Forward-EBITDA | -0.81 | |||||
| EV-to-Revenue | 0.79 | |||||
| EV-to-Forward-Revenue | 0.98 | |||||
| EV-to-FCF | -1.09 | |||||
| Price-to-Net-Current-Asset-Value | 1.64 | |||||
| Price-to-Net-Cash | 2.27 | |||||
| Earnings Yield (Greenblatt) % | -102.84 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:XGN
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 44.296 | ||
| EPS (TTM) ($) | -2.22 | ||
| Beta | 0 | ||
| Volatility % | 62.03 | ||
| 14-Day RSI | 28.98 | ||
| 14-Day ATR ($) | 0.638873 | ||
| 20-Day SMA ($) | 6.66525 | ||
| 12-1 Month Momentum % | -41.69 | ||
| 52-Week Range ($) | 4.15 - 14.9 | ||
| Shares Outstanding (Mil) | 16.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exagen Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||